- 1 Long term follow-up of colorectal cancer screening
- 2 attendees identifies differences in
- ³ Phascolarctobacterium spp. using 16S rRNA and
- 4 metagenome sequencing
- 5 Bucher-Johannessen, C.^{1,2,3}, Birkeland, E³., Vinberg, E.², Bemanian V.⁴, Hoff, G.^{5,6}, Berstad, P.⁶,
- 6 Rounge, TB.^{1,2,7}
- 7 Affiliations:
- 8 1 Department of Tumour Biology, Institute of Cancer Research, Oslo University Hospital, Norway
- 9 2 Department of Research, Cancer Registry of Norway, Norway
- 10 3 Centre for Bioinformatics, Department of Informatics, University of Oslo, Norway
- 11 4 Department of Pathology, Akershus University Hospital, Norway
- 12 5 Department of Research, Telemark Hospital Skien, Norway
- 13 6 Section for colorectal cancer screening, Cancer Registry of Norway, Oslo University Hospital, Norway
- 14 7 Centre for Bioinformatics, Department of Pharmacy, University of Oslo, Norway
- 15
- 16
- 17 Background: The microbiome has been implicated in the initiation and progression of colorectal
- 18 cancer (CRC) in cross sectional studies. However, there is a lack of studies using prospectively
- 19 collected samples.

20

Methods: We analysed 144 archived faecal samples from participants in the NORwegian
 Colorectal CAncer Prevention (NORCCAP) trial diagnosed with CRC or high-risk adenomas

(HRA) at screening, or who remained cancer-free during 17 years of follow-up. We performed
16S rRNA sequencing of all samples, and metagenome sequencing on a subset of 47 samples.
Differences in taxonomy and gene content between outcome groups were assessed for alpha
and beta diversity, and differential abundance.

27

Results: Diversity and composition analyses showed no significant differences between CRC,
HRA, and healthy controls. *Phascolarctobacterium succinatutens* was more abundant in CRC
compared to healthy controls in both the 16S and metagenome data. The abundance of *Bifidobacterium* and *Lachnospiraceae spp.* were associated with time to CRC diagnosis.

32

Conclusion: Using a longitudinal study design, we identified three taxa as being potentially
 associated with CRC. These should be the focus of further studies of microbial changes occurring
 prior to CRC diagnosis.

36

Key-words: archived faecal samples, colorectal cancer screening, microbiome, 16s rRNA
 sequencing, metagenome, long term follow-up

39 INTRODUCTION

40 CRC is the third most common cancer in men and the second in women world-wide [1, 2]. 41 Symptoms are often unspecific, and many cases are detected at an advanced stage with reduced 42 prospects for curative treatment. The progression towards CRC passes through stages of 43 molecular and morphological changes from small and benign, through advanced adenoma, and 44 finally to CRC. This adenoma-carcinoma sequence is estimated to take on average between 10-45 15 years [3]. This time window provides an opportunity to screen and potentially remove lesions 46 that have not yet developed into clinical cancer and advanced stages [3, 4]. Several randomized

studies have estimated that CRC screening by faecal tests reduces CRC mortality by 15-30% [58]. However, faecal based tests are hampered by both poor sensitivity and specificity, particularly
for detection of CRC precursor lesions [9]. Therefore, there is a need for additional markers that
can be used in faecal-based screening for CRC precursor lesions.

51 Analyses of the gut microbiome composition, diversity and functional potential have demonstrated 52 that the gut microbiome of CRC patients is different from that of their healthy counterparts, making 53 it a source of potential biomarkers for CRC [10-14]. The presence of certain microbes is strongly 54 associated with CRC. The most frequently reported are Fusobacterium nucleatum, Bacteroides 55 fragilis and pks+ Escherichia coli. Proposed mechanisms for a role of the microbiome in 56 carcinogenesis include DNA damage through secretion of genotoxic compounds, induction of 57 inflammation, and activation of pro-carcinogenic signalling pathways [15, 16]. While it has been 58 shown that faecal tests in combination with microbial biomarkers are superior at separating 59 healthy controls from CRC to that of a faecal test alone [17, 18], no specific bacterial profile is 60 recognized as a biomarker for CRC. Still less is known about the role of the microbiome in the 61 early stages of carcinogenesis.

To identify a pre-cancerous signal in the microbiome, there is a need for studies with sample collection prior to diagnosis and long-term follow-up. We performed microbiome sequencing on archived stool samples collected from screening attendees from the NORCCAP trial, with 17-year follow-up time after sigmoidoscopy screening. This study included both screening-detected cancers and CRC precursor lesions, as well as incident post-screening cancers, and healthy controls. We aimed at detecting community-wide and specific differences in the microbial profiles between CRC, HRA and healthy controls.

69 METHOD

70 Study design and participants

71 Details of the NORCCAP trial have been described previously [19-21]. Briefly, NORCCAP was a 72 randomized clinical trial including 20.780 individuals offered sigmoidoscopy screening in the 73 intervention arm and was performed in 1999-2000 (age group 55-64) and in 2001 (age group 50-74 54). The study recruited participants directly from the population registry of the Norwegian 75 counties Oslo and Telemark. All participants were examined with flexible sigmoidoscopy, while 76 10.387 participants additionally delivered stool samples for an immunochemical faecal occult blood 77 test (iFOBT - FlexSure OBT) and a fresh-frozen stool sample for biobanking. We selected a 78 subset (n=300) of participants with archived fresh-frozen faecal samples for microbiome analyses 79 (Fig. 1). Participants' full CRC history was retrieved from the Cancer Registry of Norway in 2015 80 by using personal identification numbers and included the ICD-10 coded diagnoses C18, C19, 81 and C20. Individuals with high-risk adenomas were defined as persons presenting with one or 82 more adenomas of >=10 mm, with high grade dysplasia or villous components regardless of polyp 83 size, or a person with three or more adenomas regardless of size, dysplasia and villosity. The 84 control group was selected from a pool of participants with no findings (i.e., no lesions) at the 85 screening examination (including low-risk adenomas) and who remained cancer-free during 86 follow-up. Controls were selected by matching on sex, age, and examination date. This study 87 received ethical approval from the Regional Committees for Medical and Health Research Ethics 88 in South-Eastern Norway (ref: 22337).

89 DNA-extraction, library preparation and sequencing

90 Participants were asked to collect stool samples immediately after defecation at home in 20 mL 91 vials and store the samples for at most seven days in freezer (-20 °C) before screening 92 sigmoidoscopy. Samples were delivered to either of the two screening centres in Oslo or 93 Telemark at time of sigmoidoscopy screening where further storage was at -20°C. We have

94 previously demonstrated the feasibility of obtaining microbiota profiles from these archived stool samples [22]. Prior to DNA extraction, samples were thawed, homogenised and mixed with 95 96 OMNIgene gut buffer. Extraction of DNA was carried out using the QIAsymphony automated 97 extraction system, using the QIAsymphony DSP Virus/Pathogen Midikit (Qiagen, Hilden, 98 Germany), after an off-board lysis protocol with some modifications. Each sample was lysed with 99 bead-beating: a 500 µl sample aliguot was transferred to a Lysing Matrix E tube (MP Biomedicals) 100 and mixed with 700 µl phosphate-buffered saline (PBS). The mixture was then shaken at 6.5 m/s 101 for 45 seconds. After the bead-beating, 800 µl of the sample was mixed with 1055 µl of "off-board 102 lysis buffer" (proteinase K, ATL buffer, ACL buffer and nuclease-free water) and incubated at 68°C 103 for 15 min for lysis. Nucleic acid purification was performed on the QIAsymphony extraction robot 104 using the Complex800 OBL CR22796 ID 3489 protocol. Purified DNA was eluted in 60 µI AVE-105 buffer (Qiagen, Hilden, Germany). DNA purity was assessed using a Nanodrop2000 (Thermo 106 Fisher Scientific, MA, USA), and the concentration was measured using a Qubit instrument 107 (Thermo Fisher Scientific, MA, USA).

108 After DNA-extraction and sample quality assessment, libraries were prepared for 16S rRNA and 109 shotgun metagenome sequencing. In total, 144 of available samples had sufficient DNA for 16S 110 rRNA sequencing. Sample amplification was carried out using 16S primers S-D-Bact-0341-b-S-111 17 (5'CCTACGGGNGGCWGCAG'3) and S-D-Bact-0785-a-A-21 112 (5'GACTACHVGGGTATCTAATCC' 3) to amplify the V3-V4 regions [23]. Amplification was 113 performed using the Truseq (TS)-tailed1-step amplification protocol [24] with random spacers to 114 shift the sequencing start. Paired-end 300 bp sequencing of PCR amplicons was performed on 115 the Illumina Miseg instrument (Illumina, Inc. CA, USA) (Fig. S2A). Forty-seven of the samples had 116 sufficient DNA for additional whole genome shotgun sequencing (Fig. S2B). The metagenomes 117 provide additional taxonomical resolution and improved estimates of functional potential and were 118 used for validation of the 16S rRNA sequencing results. Samples were cleaned up and

119 concentrated using AMPure XP (Beckman Coulter, IN, USA) and normalized to a total input of 4 120 ng dsDNA. Sequencing libraries were prepared using the Riptide protocol (Twist Bioscience HQ, 121 CA, USA), and sequenced on Illumina Novaseq paired end 2 x 130 bp. The Riptide protocol 122 includes linear amplification with random primers and dideoxy nucleotide-induced self-123 termination, thereby avoiding DNA fragmentation [25]. Sequencing was performed at FIMM 124 Technology Centre in Helsinki, Finland.

125 Bioinformatics analyses

126 Initial guality control of 16S sequencing reads included removal of short reads (<50bp) and low-127 quality bases with average quality across four bases below 30 using Trimmomatic (v.0.35.2) [26]. 128 Removal of primer sequences was done using Cutadapt (v.2020.2.0) [27] with the following 129 options: forward primer: CCTACGGGNGGCWGCAG, reverse primer: 130 GACTACHVGGGTATCTAATCC, primer error 0.1 and primer overlap 3. Fastqc and multiqc 131 analyses were performed before and after trimming to ensure high quality of data [28]. Reads 132 were imported into Qiime2 [29] and amplicon sequence variants (ASV) classification was 133 performed using the Divisive Amplicon Denoising Algorithm 2 (DADA2) [30] plugin, including 134 length trimming, merging, denoising and chimera removal. ASV classification was done using the 135 SILVA 16S rRNA database (v.132) at a 97 percent similarity threshold [31]. ASV data were filtered 136 for mitochondria and chloroplasts, and were rarefied to a depth of 9,000 reads for each sample. 137 Metagenome functional profiles were predicted from the 16S data using Phylogenetic 138 Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) (v.2.3.0) 139 with default settings, using rarefied count-tables as input, and mapping to MetaCyc database 140 giving pathway abundance [32].

141 Metagenome reads were trimmed using Trimmomatic (v.0.66.0) [26] with a sliding window 142 approach where reads with average quality across four bases below 30 or a read length of less 143 than 30 basepairs were discarded. Following trimming, Bowtie2 (v.2.4.2) [33] and Samtools 144 (v.1.12) [34] were used with default settings to remove reads mapping to the human genome. 145 MetaPhIAn3 (v.3.0.4) was used for taxonomic classification with default parameters [35]. Percent 146 abundances generated by MetaPhIAn3 were transformed into count-like tables by multiplying by 147 the number of quality-trimmed reads per sample and dividing by 100. HUMAnN3 was used to 148 profile genefamilies encoding microbial pathways (v.3.0.0.alpha.2), aggregating the data 149 according to MetaCyc annotations using the UniRef90 (v.201901) database [35]. Pathway 150 abundance data was corrected for sequencing depth by dividing by number of trimmed reads and 151 multiplying by 10⁶.

152 Statistical analysis

153 All statistical analyses were performed using R (v.3.5.3) and visualized using gpplot2 (v.3.3.2)[36]. 154 To assess differences between CRC, HRA and the control group, statistical tests were made 155 contrasting all three groups, or by combining CRC and HRAs. Additionally, analyses were 156 performed within the CRC group, using time to diagnosis as the dependent variable. Differences 157 between the three groups were evaluated using the Chi squared test for comparisons of two 158 categorical variables, and Kruskal Wallis test (or, for two-group comparisons, Mann-Whitney U 159 test) or Spearman's correlation for comparisons of a continuous variable with a categorical and 160 continuous variable, respectively. Statistical associations were considered significant at the 161 p<0.05 level.

Microbial diversity was measured on ASV and species level for 16S and metagenome data, respectively. Alpha diversity was determined using richness, Shannon and Inverse Simpson indexes. Beta diversity was calculated using Bray-Curtis dissimilarity, all as implemented in the

Phyloseq R package [37] (v.1.26.1). Associations between beta diversity and CRC, HRA and healthy controls were evaluated using permutational analysis of variance (PERMANOVA) with 999 permutations after adjustment for participant sex and screening centre, as implemented in the adonis function of the R package vegan (v.2.5-7).

Differential abundance analyses were performed independently on ASV/species, genus, phylum and pathways, and were adjusted for sex and screening centre. Before differential abundance analyses, we applied low abundance filtering, retaining all taxa/pathways with a read count of at least 10 in at least 10% of samples. Differential abundance analyses were performed using negative binominal model-based Wald test implemented in the DeSeq2 package with the type (poscounts) to account for the sparsity of microbiome data, and p-values were FDR adjusted to control for multiple testing (v.1.22.2) [38].

176 RESULTS

177 Study population

178

179 Stool samples from 144 NORCCAP screening participants were selected for 16S sequencing 180 based on registry follow-up data and initial screening results. Metagenome sequencing was also 181 performed on 47 of these with the highest DNA amounts. All 144 participants in this study 182 underwent sigmoidoscopy. Five cases of CRC (3.5%) were detected during screening. Based on 183 registry follow-up, 23 (16%) participants received a CRC diagnosis within 17 years after screening 184 (Fig. 2, Table 1). The median time from screening to CRC diagnosis was 7.4 years (range 0-16 185 years) and the median age at CRC diagnosis was 65.7 years (range 54-77), including both 186 screening-detected and follow-up diagnosed CRC. Other screening-detected lesions included 63 187 HRAs (44% of study participants). Fifty-three (37%) participants had no findings of adenomas or

CRC during sigmoidoscopy and were cancer free during follow-up; these constituted the control group. The median age for all groups at sample collection was 57 years (range 51-65). We observed a significantly different distribution of sex and screening centre between CRC, HRA and healthy controls (p<0.05). In total, 87 (60%) samples were from male participants and 89 (62%) samples were from the Telemark screening centre.

193 Table 1. Characteristics of study participants and samples

		16S (n=144)		Metagenome (n=47)		
Variables	Control	HRA	CRC	Control	HRA	CRC
Men (%)	36 (25)	41 (28.5)	10 (6.9)	15 (31.9)	12 (25.5)	2 (4.3)
Women (%)	17 (11.8)	22 (15.3)	18 (12.5)	7 (14.9)	6 (12.7)	5 (10.6)
Telemark (%)	39 (27)	37 (25.7)	13 (9)	16 (34)	11 (23.4)	5 (10.6)
Oslo (%)	14 (9.7)	26 (18)	15 (10.5)	6 (12.8)	7 (14.9)	2 (4.3)
Age at sampling, median (range)	57 (51-64)	57 (51-64)	60.5 (51-65)	57 (54-64)	58 (53-64)	61 (55-65)
Age at diagnoses, median (range)	-	-	65.7 (54-77)	-	-	65.8 (61.1-74.3)
Time to diagnosis, median (range)	-	-	7.4 (0-16)	-	-	4.8 (0-14)
Reads, median (range)	61,184 (10,261- 416,286)	48,014 (5,163- 493,315)	48,314 (23,701- 510,589)	7,356,487 (757,832- 16,480,67 4)	5,146,988 (998,978- 20,095,193)	7,248,142 (1,757,061- 15,370,089)
Excluded	0	2¤*	0	0	1*	0

194 ¤ one person was excluded from 16S diversity analyses due to rarefaction criterion of at least 9000 reads * one 195 person was excluded from all analyses (in both 16S and metagenome dataset) because of an E. coli infection

197 Gut microbiome diversity

198 16S sequencing of 144 samples generated 11.8 million trimmed reads with a median read depth 199 per sample of 50,205 (range 5,163-510,589). We identified in total 7,228 ASVs mapped to 337 200 species, 229 genus and 18 phyla. The median number of observed ASVs was 213.5 (range 79-201 603). Metagenomic sequencing of 47 samples resulted in 361 million trimmed reads with a median 202 read depth of 6.2 million reads (0.76-20.1). In total, 561 taxa were identified, including 323 203 species, 116 genus and 8 phyla. The median number of species per sample was 73 (34-107). 204 ASV distribution for individual samples showed one sample with 83% of reads belonging to two 205 ASVs within the genus Escherichia-Shigella. This was confirmed in the metagenome data where 206 95% of reads belonged to the species Escherichia coli. As this indicated an unrelated acute 207 infection, the sample was excluded from further analyses (Fig. S1).

208

Rarefying 16S data to 9,000 reads resulted in exclusion of one sample with lower sequencing coverage, leaving 142 samples for 16S diversity analyses. Forty-six samples were used for metagenome diversity analyses. We found no significant differences in alpha (unadjusted) or beta diversity of taxa or pathways between CRC, HRA and healthy controls (Fig. 3A-D, 4A-D, p>0.05 for all comparisons). This finding remained consistent when grouping CRC and HRA cases together, when looking at time to diagnosis, when considering metagenome data, and when adjusting for sex and screening centre.

216 Differentially abundant taxa and pathways

We evaluated differences in abundance of individual taxa and pathways between the outcome groups using the abundance of ASV/species, genus, phylum or pathways. We further assessed associations of ASVs with the time elapsed from sample collection to CRC diagnosis.

220 CRC vs. Control

For the 16S data, the ASV *Phascolarctobacterium uncultured bacterium* and the phylum *Firmicutes* were significantly more abundant in CRC than controls (FDR p<0.05, Table 2 and Fig. 5A). Similarly, in the metagenome data *Phascolarctobacterium succinatutens* was significantly more abundant in CRC. For the metagenome data, in total 9 species were differentially abundant (FDR p<0.05, Table 2 and Fig. 5C). Five of these were significantly higher in CRC compared to control, whereas 4 were significantly lower. The genus *Acidaminococcus* was significantly higher in CRC. Four pathways were significantly lower in CRC compared to controls.

HRA vs. Control

229 For 16S data, the genera Azospirillum sp. 47 25 and Escherichia-Shigella were lower in HRA 230 compared to controls (FDR p<0.05, Table 2 and Fig. 5A). The phyla Proteobacteria and 231 Firmicutes were lower and higher in HRA compared to controls, respectively. The direction of 232 differences for these phyla was similar in the metagenome data, though not significant. Twenty 233 pathways were lower in HRA based on 16S data. Of these, three pathways were related to heme 234 biosynthesis: HEMESYN2-PWY (heme biosynthesis II (anaerobic)), PWY-5920 (superpathway of 235 heme biosynthesis from glycine), and PWY0-1415 (superpathway of heme biosynthesis from 236 uroporphyrinogen-III) (FDR p<0.05, Table 2 and Fig. 5B). The direction was similar for PWY0-237 1415 in the metagenome data. We also observed differences in REDCITCYC (TCA cycle VIII 238 (helicobacter)) and the closely related pathways PWY0-42 (methylcitrate cycle I), PWY-5747 239 (methylcitrate cycle II) and GLYOXYLATE-BYPASS (glyoxylate cycle). For metagenome data the 240 species Clostridium saccharolyticum was significantly higher and genus Parasutterella was 241 significantly lower in HRA compared to controls (FDR p<0.05, Table 2 and Fig. 5C).

242 HRA&CRC vs. Control

For 16S, when considering HRA and CRC as one group and comparing it to controls, the phylum *Firmicutes* was significantly higher in HRA/CRC (FDR p<0.05, Table 2 and Fig. 5A). The same non-significant trend was observed in the metagenome data. Pathways CENTFERM-PWY (pyruvate fermentation to butanoate) and PWY-6590 (superpathway of Clostridium acetobutylicum acidogenic fermentation) were lower in HRA/CRC (FDR p<0.05, Table 2 and Fig. 5B). For metagenome data, the species *Clostridium saccharolyticum* was significantly more abundant in the HRA/CRC group (FDR p<0.05, Table 2 and Fig. 5C).

250 Time to diagnosis

Assessing the CRC group only, those with a longer interval between sample collection and diagnosis had higher abundance of one genus, *Bifidobacterium* and one ASV within the *Lachnospiraceae* family. Additionally, three ASVs within *Lachnospiraceae* were lower in those with a long time to diagnosis (FDR p<0.05, Fig. 6 and Table 2).

255 DISCUSSION

Using both 16S rRNA and metagenome sequencing data, we analysed the microbial differences between CRC, HRA and healthy controls of 144 screening attendees with long-term follow-up data. *Phascolarctobacterium spp.*, were more abundant in the CRC compared to controls and four ASVs belonging to the *Lachnospiraceae* family, and *Bifidobacterium* were associated with time to CRC diagnosis. Several heme biosynthesis pathways were less abundant in HRA. We did not observe compositional differences between CRC, HRA and healthy controls, and identified no correlation between richness and time to diagnosis in the CRC group.

263 We identified Phascolarctobacterium uncultured bacterium and Phascolarctobacterium 264 succinatutens in the 16S and metagenome data respectively, as being significantly higher in CRC 265 compared to healthy controls. These annotations likely represent the same species. Three studies 266 have reported similar findings [39-41]. Interestingly, [41] et al. found an elevation in P. 267 succinatutens in the early stages of CRC, from polypoid adenomas to stage 1 CRC. P. 268 succinatutens is broadly distributed in the GI tract and converts succinate into propionate. The 269 strain can likely not ferment any other short-chain fatty acids or carbohydrates [42]. Succinate is 270 a tricarboxylic acid (TCA) cycle intermediate and is produced both by the host and the microbiota. 271 including CRC-associated bacteria B. fragilis and F. nucleatum. Increased succinate in the colon 272 has been linked to gut inflammation and disease, while increased propionate is thought to be anti-273 inflammatory [43, 44]. Succinate is proposed to mediate cross-talk as a signaling metabolite that 274 act as a positive regulator of intestinal gluconeogenesis [44, 45] and thermogenesis [46] We also 275 report several pathways related to the TCA-cycle to be lower in HRA compared to controls. [47] 276 et al found this pathway to be increased in cancer.

Three pathways related to heme biosynthesis were significantly lower in the HRA group compared to controls. While heme uptake, biosynthesis and export in bacteria are not fully understood [48, 49], bleeding tumours release heme into the gut lumen. This might create a niche for heme scavenging bacteria which could outcompete those who rely on heme biosynthesis.

Bifidobacterium and four ASVs belonging to *Lachnospiraceaecea* family were associated with time to diagnosis. Bifidobacterium is a lactic acid producing bacteria, aiding in colonocyte renewal and inhibiting growth of pathogens. Two studies found Bifidobacterium to be lower in persons with lesions compared to controls [3, 50]. This is in line with our findings that lower levels are associated with a shorter time to diagnosis. We observed different members of the *Lachnospiraceaecea* family showing diverging associations with time to diagnosis. This family was found to be enriched in controls compared to patients with lesions [51]. Some members of

the *Lachnospiraceaecea* family can produce the short-chain fatty acid butyrate [52]. Butyrate aids in cell renewal of colonocytes, serves as a carbon source for the TCA cycle, and has antiinflammatory and anti-tumorigenic properties [53, 54].

291 We found no difference in diversity or composition between CRC, HRA and controls, Results from 292 similar studies seem to be conflicting, both for diversity and composition analyses. [11, 55-58]. 293 Smaller differences in the microbiome of adenomas and healthy controls have been observed 294 than those observed between cancers and healthy controls [3, 11]. Unlike previous studies in the 295 field, many of our samples were collected from asymptomatic subjects, years before diagnosis of 296 cancer. While our results indicate no overall difference in diversity or composition, it is possible 297 that we have been underpowered or that factors related to study design and technical challenges 298 have led us to miss any small differences in these ecological measures.

299 This study has some other noteworthy limitations. Firstly, our samples were stored for 17 years 300 and could possibly be degraded. We do know that these samples have few freeze-thaw cycles 301 [22], but they were stored without a stabilizing agent which could to some extent influence the 302 composition of faecal samples [59, 60]. Further, we lack information on important confounding 303 factors such as diet, lifestyle factors, body mass index, and antibiotics use affecting microbiome 304 composition [53, 61]. Lastly, we observed a high abundance of the phylum *Firmicutes* in our 16S 305 data, but a similar composition was not observed for the metagenome data. This is likely due to 306 the choice of primers, where for marker gene studies, certain primers favour the amplification of 307 specific taxa [62]. Still, this did likely not affect the differential abundance analyses, as the bias 308 was uniform across samples.

309 Conclusions

The present study is, to the best of our knowledge, the first to examine gut microbiome samplescollected several years prior to CRC diagnosis. We did not find any differences between diversity

and composition of the gut microbiome and the presence of CRC, HRA, and controls. However, analyses identified several taxa and pathways that were differentially abundant. Our study found that the succinate-metabolising, associated with inflammation,__*Phascolarctobacterium succinatutens* was more prevalent in individuals diagnosed with CRC than in healthy controls, identified using both 16S and metagenome data. In this population-based screening setting we also show that CRC-associated taxa are identifiable years prior to diagnosis of CRC.

- 319 Declarations
- 320 Ethics approval and consent to participate

321 This study received ethical approval from the Regional Committees for Medical and Health

- 322 Research Ethics in South-Eastern Norway (ref: 22337).
- 323 Consent for publication
- 324 Not applicable
- 325 Availability of data and materials
- 326 The datasets generated and/or analysed during the current study are not publicly available
- 327 because this is human data and individuals' privacy could be compromised but data is available
- 328 from the corresponding author on reasonable request.
- 329 Competing interests
- 330 The authors declare that they have no competing interests

331 Funding

Data analyses and writing this manuscript are a part of the PhD work of CBJ which is funded by
 South-Eastern Norway Regional Health Authority. Lab work including DNA isolation, library
 preparation and sequencing and also data management and project coordination is funded by the
 Cancer Registry of Norway funds.

336 Authors' contributions

TBR and GH designed the study. CBJ and EB analysed the data. EV and VB performed sample
 preparation and lab work. CBJ, EB and TBR drafted the manuscript. All authors commented and
 approved the final manuscript.

340 Acknowledgements

341 We would like to thank Jan Inge Nordby for his contribution on sample preparation and lab work. 342 Library preparation and sequencing was performed at FIMM Technology Centre supported by 343 HiLIFE and Biocenter Finland. Especially, we would like to thank Tiina Hannunen, Harri A. Kangas 344 and Pekka J. Ellonen for the good cooperation, service and communication. We would also like 345 to acknowledge Even Sannes Riiser for his early contributions on lab coordination and 346 bioinformatics analyses. Finally, this article is a result of cooperations and scientific discussions 347 among colleagues in our research group. Therefore, we want to thank Ane Sørlie Kværner, 348 Ekaterina Avershina, Paula Istvan and Maja Jacobsen.

- 349
- 350
- 351
- 352
- 353
- 354

355		References
357 358	1.	Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB: Colorectal cancer . <i>The Lancet</i> 2019, 394 (10207):1467-1480.
359 360 361	2.	Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F: Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. <i>Gut</i> 2022.
362 363 364	3.	Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z <i>et al</i> : Gut microbiome development along the colorectal adenoma-carcinoma sequence . <i>Nat Commun</i> 2015, 6 :6528.
365	4.	Brenner H, Kloor M, Pox CP: Colorectal cancer. The Lancet 2014, 383(9927):1490-1502.
366 367 368 369	5.	Chiu HM, Chen SL, Yen AM, Chiu SY, Fann JC, Lee YC, Pan SL, Wu MS, Liao CS, Chen HH <i>et al</i> : Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. <i>Cancer</i> 2015, 121 (18):3221-3229.
370 371 372 373	6.	Giorgi Rossi P, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, Mangone L, Pezzarossi A, Roncaglia F, Campari C <i>et al</i> : Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy . <i>The American journal of gastroenterology</i> 2015, 110 (9):1359-1366.
374 375	7.	Lindholm E, Brevinge H, Haglind E: Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. <i>Br J Surg</i> 2008, 95 (8):1029-1036.
376 377 378	8.	Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, Church TR: Long- term mortality after screening for colorectal cancer. <i>N Engl J Med</i> 2013, 369 (12):1106-1114.
379 380 381	9.	Ribbing Wilen H, Blom J, Hoijer J, Andersson G, Lowbeer C, Hultcrantz R: Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives. <i>Scandinavian journal of gastroenterology</i> 2019, 54 (3):303-310.
382 383 384	10.	Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y <i>et al</i> : Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer . <i>Gut</i> 2017, 66 (1):70-78.
385 386 387 388	11.	Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C <i>et al</i> : Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation . <i>Nat Med</i> 2019, 25 (4):667-678.

- Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, Dong W, Liu X, Wang S, Zhong W *et al*:
 Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor
 development through modulating Wnt signaling and gut microbiota. *Cancer Lett* 2020, 469:456-467.
- 393 13. Rebersek M: Gut microbiome and its role in colorectal cancer. *BMC cancer* 2021, 21(1):1325.
- Yang J, Li D, Yang Z, Dai W, Feng X, Liu Y, Jiang Y, Li P, Li Y, Tang B *et al*: Establishing
 high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in
 patients with healthy families. *Gut Microbes* 2020, 11(4):918-929.
- Pleguezuelos-Manzano C, Puschhof J, Clevers H: Gut Microbiota in Colorectal Cancer:
 Associations, Mechanisms, and Clinical Approaches. Annual Review of Cancer
 Biology 2021, 6(1).
- 40116.Wong SH, Yu J: Gut microbiota in colorectal cancer: mechanisms of action and
clinical applications. Nat Rev Gastroenterol Hepatol 2019, 16(11):690-704.
- 403 17. Wong SH, Kwong TNY, Chow TC, Luk AKC, Dai RZW, Nakatsu G, Lam TYT, Zhang L,
 404 Wu JCY, Chan FKL *et al*: Quantitation of faecal Fusobacterium improves faecal
 405 immunochemical test in detecting advanced colorectal neoplasia. *Gut* 2017,
 406 66(8):1441-1448.
- 407 18. Yuan B, Ma B, Yu J, Meng Q, Du T, Li H, Zhu Y, Sun Z, Ma S, Song C: Fecal Bacteria
 408 as Non-Invasive Biomarkers for Colorectal Adenocarcinoma. Front Oncol 2021,
 409 11:664321.
- Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, Eide TJ, Skovlund E,
 Schneede J, Tveit KM *et al*: Effect of flexible sigmoidoscopy screening on colorectal
 cancer incidence and mortality: a randomized clinical trial. JAMA 2014, 312(6):606615.
- Bretthauer M, Gondal G, Larsen K, Carlsen E, Eide TJ, Grotmol T, Skovlund E, Tveit KM,
 Vatn MH, Hoff G: Design, organization and management of a controlled population
 screening study for detection of colorectal neoplasia: attendance rates in the
 NORCCAP study (Norwegian Colorectal Cancer Prevention). Scandinavian journal of
 gastroenterology 2002, 37(5):568-573.
- Bretthauer M, Thiis-Evensen E, Huppertz-Hauss G, Gisselsson L, Grotmol T, Skovlund E,
 Hoff GJG: NORCCAP (Norwegian colorectal cancer prevention): a randomised trial
 to assess the safety and efficacy of carbon dioxide versus air insufflation in
 colonoscopy. 2002, 50(5):604-607.
- 423 22. Rounge TB, Meisal R, Nordby JI, Ambur OH, de Lange T, Hoff G: Evaluating gut
 424 microbiota profiles from archived fecal samples. *BMC Gastroenterol* 2018, **18**(1):171.

- 425 23. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, Glockner FO:
 426 Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next427 generation sequencing-based diversity studies. Nucleic Acids Res 2013, 41(1):e1.
- Raju SC, Lagström S, Ellonen P, de Vos WM, Eriksson JG, Weiderpass E, Rounge TB:
 Reproducibility and repeatability of six high-throughput 16S rDNA sequencing protocols for microbiota profiling. *J Microbiol Methods* 2018, **147**:76-86.
- 431 25. Siddique A, Suckow G, Bahena J, Homer N, Ordoukhanian P, Head S, Brown K: RipTide
 432 Ultra High-Throughput Rapid DNA Library Preparation for Next Generation
 433 Sequencing. Journal of Biomolecular Techniques: JBT 2019, 30(Suppl):S36.
- 434 26. Bolger AM, Lohse M, Usadel B: Trimmomatic: a flexible trimmer for Illumina sequence
 435 data. *Bioinformatics* 2014, **30**(15):2114-2120.
- 436 27. Martin M: Cutadapt removes adapter sequences from high-throughput sequencing
 437 reads. 2011 2011, 17(1):3 %J EMBnet.journal.
- Ewels P, Magnusson M, Lundin S, Kaller M: MultiQC: summarize analysis results for
 multiple tools and samples in a single report. *Bioinformatics* 2016, 32(19):3047-3048.
- Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H,
 Alm EJ, Arumugam M, Asnicar F *et al*: Reproducible, interactive, scalable and
 extensible microbiome data science using QIIME 2. Nat Biotechnol 2019, 37(8):852857.
- Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP: DADA2: Highresolution sample inference from Illumina amplicon data. Nat Methods 2016,
 13(7):581-583.
- 447 31. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO:
 448 The SILVA ribosomal RNA gene database project: improved data processing and
 449 web-based tools. Nucleic Acids Res 2013, 41(Database issue):D590-596.
- 450 32. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower C,
 451 Langille MGI: PICRUSt2 for prediction of metagenome functions. Nat Biotechnol 2020,
 452 38(6):685-688.
- 453 33. Langmead B, Trapnell C, Pop M, Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 2009, 10(3):R25.
- 456 34. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin
 457 R, Genome Project Data Processing S: The Sequence Alignment/Map format and
 458 SAMtools. *Bioinformatics* 2009, 25(16):2078-2079.

35. Beghini F, McIver LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A,
Manghi P, Scholz M, Thomas AM *et al*: Integrating taxonomic, functional, and strainlevel profiling of diverse microbial communities with bioBakery 3. *Elife* 2021, 10.

- 462 36. Wickham H: ggplot2: elegant graphics for data analysis: Springer; 2016.
- 463 37. McMurdie PJ, Holmes SJPo: phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. 2013, 8(4):e61217.
- 465 38. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for
 466 RNA-seq data with DESeq2. *Genome Biol* 2014, 15(12):550.
- 467 39. Yang HJ, Kwon MJ, Chang Y, Song SK, Ahn KS, Kim HN, Yun Y, Kim HL, Park DI: Fecal
 468 Microbiota Differences According to the Risk of Advanced Colorectal Neoplasms. J
 469 Clin Gastroenterol 2019, 53(3):197-203.
- 470 40. Zackular JP, Rogers MA, Ruffin MTt, Schloss PD: The human gut microbiome as a
 471 screening tool for colorectal cancer. *Cancer Prev Res (Phila)* 2014, 7(11):1112-1121.
- 472 41. Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H,
 473 Masuda K, Nishimoto Y, Kubo M *et al*: Metagenomic and metabolomic analyses reveal
 474 distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. *Nat*475 *Med* 2019, 25(6):968-976.
- 476 42. Watanabe Y, Nagai F, Morotomi M: Characterization of Phascolarctobacterium succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated from human feces. *Appl Environ Microbiol* 2012, **78**(2):511-518.
- 479 43. Ternes D, Karta J, Tsenkova M, Wilmes P, Haan S, Letellier E: Microbiome in Colorectal
 480 Cancer: How to Get from Meta-omics to Mechanism? *Trends Microbiol* 2020,
 481 28(5):401-423.
- 482 44. Fernandez-Veledo S, Vendrell J: Gut microbiota-derived succinate: Friend or foe in
 483 human metabolic diseases? *Rev Endocr Metab Disord* 2019, 20(4):439-447.
- 484 45. De Vadder F, Kovatcheva-Datchary P, Zitoun C, Duchampt A, Backhed F, Mithieux G:
 485 Microbiota-Produced Succinate Improves Glucose Homeostasis via Intestinal
 486 Gluconeogenesis. *Cell Metab* 2016, 24(1):151-157.
- 487 46. Mills EL, Pierce KA, Jedrychowski MP, Garrity R, Winther S, Vidoni S, Yoneshiro T,
 488 Spinelli JB, Lu GZ, Kazak L *et al*: Accumulation of succinate controls activation of
 489 adipose tissue thermogenesis. *Nature* 2018, 560(7716):102-106.
- 490 47. Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt AY, Hercog R, Goedert JJ, Shi J, Bork
 491 P, Sinha R: Colorectal Cancer and the Human Gut Microbiome: Reproducibility with
 492 Whole-Genome Shotgun Sequencing. *PloS one* 2016, **11**(5):e0155362.

- 493 48. Donegan RK: The role of host heme in bacterial infection. *Biol Chem* 2022, 403(11494 12):1017-1029.
- 495 49. Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E: **The Multifaceted Role of** 496 **Heme in Cancer**. *Front Oncol* 2019, **9**:1540.
- 497 50. Rezasoltani S, Asadzadeh Aghdaei H, Dabiri H, Akhavan Sepahi A, Modarressi MH, Nazemalhosseini Mojarad E: The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. *Microb Pathog* 2018, 124:244-249.
- 50151.Baxter NT, Ruffin MTt, Rogers MA, Schloss PD: Microbiota-based model improves the
sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med
2016, 8(1):37.
- 50452.Meehan CJ, Beiko RG: A phylogenomic view of ecological specialization in the
Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol5062014, 6(3):703-713.
- 507 53. O'Keefe SJ: **Diet, microorganisms and their metabolites, and colon cancer**. *Nat Rev* 508 *Gastroenterol Hepatol* 2016, **13**(12):691-706.
- 509 54. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ: **The microbiology of butyrate** 510 **formation in the human colon**. *FEMS microbiology letters* 2002, **217**(2):133-139.
- 511 55. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, Moris F,
 512 Bodrigo L, Mira A, Collado MC: Microbial mucosal colonic shifts associated with the
 513 development of colorectal cancer reveal the presence of different bacterial and
 514 archaeal biomarkers. *J Gastroenterol* 2015, **50**(2):167-179.
- 515 56. Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L: Human
 516 gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013, 105(24):1907517 1911.
- 518 57. Zhang H, Chang Y, Zheng Q, Zhang R, Hu C, Jia W: **Altered intestinal microbiota** 519 **associated with colorectal cancer**. *Front Med* 2019, **13**(4):461-470.
- 520 58. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A,
 521 Ponnudurai R *et al*: Meta-analysis of fecal metagenomes reveals global microbial
 522 signatures that are specific for colorectal cancer. *Nat Med* 2019, 25(4):679-689.
- 523 59. Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL: Methods for
 524 Improving Human Gut Microbiome Data by Reducing Variability through Sample
 525 Processing and Storage of Stool. *PloS one* 2015, **10**(8):e0134802.

- 52660.Flores R, Shi J, Yu G, Ma B, Ravel J, Goedert JJ, Sinha R: Collection media and delayed527freezing effects on microbial composition of human stool. Microbiome 2015, 3:33.
- 528 61. Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R, Belkaid Y: **Host variables confound gut microbiota studies of human disease**. *Nature* 2020, **587**(7834):448-454.
- 530 62. Soergel DA, Dey N, Knight R, Brenner SE: Selection of primers for optimal taxonomic
 531 classification of environmental 16S rRNA gene sequences. *ISME J* 2012, 6(7):1440532 1444.

- _ . _

- _ . .



554 555

Figure 1 Recruitment flowchart. Half of the NORCCAP participants were invited to deliver a stool sample in addition 556 to participating in sigmoidoscopy screening. Half of these faecal samples were stored below -20°C. A subset of 557 samples diagnosed with CRC, HRA and matched controls were included in the study and homogenised in 558 preservation buffers. Those with sufficient DNA extracted were included in 16S rRNA (n=144) and metagenome

559 sequencing (n=47). FS fecal sigmoidoscopy, FOBT fecal occult blood test.

560



Figure 2 Overview of time from sample collection to cancer diagnosis for the 23 study participants who received a CRC diagnosis during screening or follow-up. Five participants with time to diagnosis ≤ 0.1 years received the diagnosis during screening.



588 589

Figure 3 Alpha diversity: box plots with taxa/pathway richness (Observed), and Shannon and Inverse Simpson (InvSimpson) diversity indices in CRC, HRA and controls for A) amplicon sequence variants from 16S sequencing data
B) estimated MetaCyc pathways derived from 16S data C) Species abundance based on metagenome shotgun sequencing D) Metacyc pathways based on metagenome shotgun sequencing.



Figure 4 Beta diversity: PCoA plots with Bray Curtis dissimilarity indices between CRC, HRA and controls for A) amplicon sequence variants from 16S sequencing data B) MetaCyc pathways derived from 16S sequencing data C) Species abundance based on metagenome shotgun sequencing D) Metacyc pathways based on metagenome shotgun sequencing. Ellipses describe 95% of group variation for the principal coordinate axes.



Figure 5 Volcano plots showing differences in abundance of taxa and pathways between groups. FDR-significant differentially abundant taxa or pathways are highlighted in red. Group comparisons are indicated by different shapes where the control group or a shorter time to diagnosis is considered the reference. Differential abundance was analysed for A) amplicon sequence variants from 16S sequencing data B) MetaCyc pathways derived from 16S sequencing data C) Species abundance based on metagenome shotgun sequencing D) Metacyc pathways based on metagenome shotgun sequencing E) amplicon sequence variants from 16S sequencing data and time to CRC diagnosis.

617 Table 2 Differential abundance aalyses of taxa and pathways between CRC, HRA and healthy controls. Log-2foldchange indicates the magnitude and direction of

618 difference in abundance. Analyses were adjusted for sex and screening centre.

Contrast	baseMean	log2FoldChange	padj	Taxa/Pathway
				ASV taxonomy, n=143
Control vs CRC	41,37	11,16	0,0072	Phascolarctobacterium uncultured bacterium
Control vs CRC	61410,72	0,63	0,0366	Firmicutes
Control vs HRA	33,60	-4,10	0,0464	Azospirillum sp. 47_25
Control vs HRA	303,86	-3,47	0,0498	Escherichia-Shigella
Control vs HRA	662,44	-1,83	0,0028	Proteobacteria
Control vs HRA	61410,72	0,44	0,0374	Firmicutes
Control vs HRA/CRC	61410,72	0,50	0,0131	Firmicutes
				ASV pathways, n=143
Control vs HRA	181,995	-1,125	1,80E-05	CENTFERM-PWY: pyruvate fermentation to butanoate
Control vs HRA	135,426	-1,240	0,0002	FAO-PWY: fatty acid β-oxidation I
Control vs HRA	48,787	-1,325	0,0397	GALACTARDEG-PWY: D-galactarate degradation I
Control vs HRA	48,787	-1,325	0,0397	GLUCARGALACTSUPER-PWY: superpathway of D-glucarate and D-galactarate degradation
Control vs HRA	45,812	-2,299	0,0165	GLYCOL-GLYOXDEG-PWY: superpathway of glycol metabolism and degradation
Control vs HRA	60,372	-2,383	0,0155	GLYOXYLATE-BYPASS: glyoxylate cycle
Control vs HRA	179,086	-0,713	0,0318	HEMESYN2-PWY: heme biosynthesis II (anaerobic)
Control vs HRA	94,118	-0,814	0,0155	PWY-5177: glutaryl-CoA degradation
Control vs HRA	25,662	-2,439	0,0333	PWY-5747: 2-methylcitrate cycle II
Control vs HRA	58,730	-2,176	0,0029	PWY-5855: ubiquinol-7 biosynthesis (prokaryotic)
Control vs HRA	58,730	-2,176	0,0029	PWY-5856: ubiquinol-9 biosynthesis (prokaryotic)
Control vs HRA	58,730	-2,176	0,0029	PWY-5857: ubiquinol-10 biosynthesis (prokaryotic)
Control vs HRA	29,454	-1,915	0,0397	PWY-5920: superpathway of heme biosynthesis from glycine
Control vs HRA	230,973	-1,105	1,80E-05	PWY-6590: superpathway of Clostridium acetobutylicum acidogenic fermentation
Control vs HRA	58,730	-2,176	0,0029	PWY-6708: ubiquinol-8 biosynthesis (prokaryotic)
Control vs HRA	60,697	-1,262	0,0165	PWY0-1415: superpathway of heme biosynthesis from uroporphyrinogen-III
Control vs HRA	132,568	-1,063	0,0317	PWY0-1533: methylphosphonate degradation I
Control vs HRA	25,410	-2,461	0,0397	PWY0-42: 2-methylcitrate cycle I
Control vs HRA	468,521	-0,711	0,0155	REDCITCYC: TCA cycle VIII (helicobacter)

Control vs HRA	56,227	-2,187	0,0029	UBISYN-PWY: superpathway of ubiquinol-8 biosynthesis (prokaryotic)		
Control vs HRA/CRC	181,995	-0,965	0,0002	CENTFERM-PWY: pyruvate fermentation to butanoate		
Control vs HRA/CRC	230,973	-0,949	0,0002	PWY-6590: superpathway of Clostridium acetobutylicum acidogenic fermentation		
Metagenome taxonomy, n=46						
Control vs CRC	3436,272	-30	1,07E-09	Bacteroides finegoldii		
Control vs CRC	1543,539	11,06101	3,12E-02	Lactobacillus rogosae		
Control vs CRC	3173,952	-12,5276	4,94E-02	Monoglobus pectinilyticus		
Control vs CRC	80657,51	6,196732	2,21E-03	Coprococcus eutactus		
Control vs CRC	4742,03	-16,8273	2,57E-03	Roseburia sp. CAG:303		
Control vs CRC	1160,284	13,24881	3,12E-02	Firmicutes bacterium CAG:95		
Control vs CRC	3457,533	18,9179	4,59E-04	Acidaminococcus intestini		
Control vs CRC	19999,34	20,45545	2,88E-05	Phascolarctobacterium succinatutens		
Control vs CRC	2400,172	-30	1,35E-11	Veillonella parvula		
Control vs CRC	3264,922	19,253	0,0001	Acidaminococcus		
Control vs HRA	511,8308	15,320	0,0002	Clostridium saccharolyticum		
Control vs HRA	1584,142	-30,000	7,13E-19	Parasutterella		
Control vs HRA/CRC	511,8308	12,21184	0,0031	Clostridium saccharolyticum		
Metagenome pathways, n=46						
Control vs CRC	13,053	-24,231	5,64E-06	ENTBACSYN-PWY: enterobactin biosynthesis		
Control vs CRC	20,312	-22,480	2,46E-08	PWY-6285: superpathway of fatty acids biosynthesis (E. coli)		
Control vs CRC	5,721	-20,822	6,05E-06	PWY-6992: 1,5-anhydrofructose degradation		
Control vs CRC	3,859	-24,204	6,05E-06	THREOCAT-PWY: superpathway of L-threonine metabolism		
ASV taxonomy: time to CRC diagnosis, n=28						
Time	18,42315	1,251612	0,0008	Bifidobacterium		
Time	19,47221	-1,20951	0,0006	Lachnospiraceae		
Time	11,94936	-1,47904	0,0001	Lachnospiraceae		
Time	7,238016	-1,32495	0,0006	Lachnospiraceae		
Time	13,97661	1,171725	0,0023	Lachnospiraceae		